<meta http-equiv="content-type" content="text/html; charset=ISO-8859-1" /><br>Title: Cost-effectiveness of Risk-factor Guided and Universal Screening for Chronic Hepatitis C</br><br>Author: Shan Liu, Stanford University, Stanford, CA, 94305, United States of America, shanliu@stanford.edu</br><br>Coauthor(s): Lauren Cipriano, Mark Holodniy, Jeremy Goldhaber-Fiebert</br><br>Year: 2012</br><br>Abstract: U.S. guidelines conflict over population screening for chronic hepatitis C. We assessed the cost-effectiveness of universal and risk-factor guided screening for asymptomatic adults followed by one of three treatment strategies. Statistical analyses of the National Health and Nutrition Examination Survey estimated sex-, race-, age-specific risk factor prevalence and mortality risks. Universal screening is likely cost-effective.</br>